Welcome
By selecting the Yes, leave Opcaseportalmy.com option you understand that you are leaving the website and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Malaysia is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third-party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Malaysia. If you reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Explore Cases
This curated collection of patient case studies aims to provide healthcare practitioners in the area of bone health, with a comprehensive understanding of risk-based treatment approach in the long-term management of patients living with osteoporosis.
The patient cases were contributed by bone health experts from respective clinical setting, incorporating evidence-based discussions, guidelines and clinical considerations in the individualised treatment sequencing plans of different real-world scenarios.
Disclaimer
- The cases contributed by bone health experts and contents in this case binder reflect real life practices in the clinical setting, therefore may contain differing practices, information on research activities and may refer to products not approved for use, and/or unapproved uses of products approved in Malaysia.
- Amgen Malaysia does not endorse the promotion of unapproved products or indications. Please refer to the approved prescribing information in Malaysia.
- The management of patients would be at the discretion of treating physician, according to clinical judgement and individual patient’s risk-benefit assessment.
- For further information on Amgen products or to report an adverse event involving an Amgen product, please contact Medical Information at 1800 818 227 or medinfo.JAPAC@amgen.com.
Explore Cases
Explore Cases
Case 1: 70-year-old female with bilateral hip osteoarthritis
Romosozumab ➝ Denosumab
Explore Cases
Case 2: 87-year-old female with left neck of femur fracture
Denosumab ➝ Romosozumab
Explore Cases
Case 3: 62-year-old postmenopausal female with vertebral fracture
Romosozumab ➝ Denosumab
Explore Cases
Case 4: 84-year-old female with multiple fragility fractures
Teriparatide ➝ Denosumab
Explore Cases
Case 5 : 48-year-old female with history of TAHBSO
Romosozumab ➝ Alendronate
-
Important Safety Information:Osteoporosis Case BinderThis curated collection of patient case studies aims to provide healthcare practitioners in the area of bone health, with a comprehensive understanding of risk-based treatment approach in the long-term management of patients living with osteoporosis.The patient cases were contributed by bone health experts from respective clinical setting, incorporating evidence-based discussions, guidelines and clinical considerations in the individualised treatment sequencing plans of different real-world scenarios..Please review full product information before prescribingFor Healthcare Professionals Only.Please refer to full prescribing information prior to administrationFor information on Amgen products or to report an adverse event involving an Amgen product, please contact Medical Information at 1800 818 227 or medinfo.JAPAC@amgen.comSC-MAL-CP-00128-0425Endorsed By:
